Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Zoetis (ZTS)
NYSE:ZTS
Zoetis (ZTS) Stock Price & Analysis
3,173 Followers
ZTS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$144.80 - $200.89
Previous Close$174.06
Volume2.00M
Average Volume (3M)3.69M
Market Cap
$79.42B
Enterprise Value$86.17B
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$6.75B
Price to Earnings (P/E)33.6
Beta1.15
Next Earnings
Aug 01, 2024EPS Estimate
$1.5Last Dividend Ex-Date
Apr 18, 2024Dividend Yield0.93%
Share Statistics
EPS (TTM)5.19
Shares Outstanding456,295,137
10 Day Avg. Volume2,569,890
30 Day Avg. Volume3,690,414
Standard Deviation0.07
R-Squared0.39
Alpha0.00184
Financial Highlights & Ratios
Price to Book (P/B)88.07
Price to Sales (P/S)9.30
Price to Cash Flow (P/CF)22.10
P/FCF Ratio26.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue10.09
Enterprise Value/Gross Profit14.40
Enterprise Value/Ebitda23.51
Forecast
1Y Price Target
$205.00Price Target Upside17.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Zoetis News
Bulls Say, Bears Say
Bulls Say
Product EfficacyEncouraging launch metrics and positive views from Key Opinion Leaders on Zoetis' OA pain mAbs support strong prospects, alongside confidence in the efficacy and long-term outlook of Librela.
Product LaunchZoetis is anticipated to have strong uptake of key new products, with management's confidence reflected in robust revenue estimates, indicating potential market growth.
Safety And Regulatory StatusVeterinarian feedback suggests Librela is well-received for its benefits and safety, with low adverse events rates and routine regulatory interactions post-launch, hinting at a stable market presence.
Bears Say
Financial PerformanceForecasts are tempered by foreign exchange headwinds.
Increased CostsHigher operating expenses are expected due to increased spending to defend key brands and support new launches.
Regulatory ChallengesEC announces antitrust investigation on pain mAb development.
---
Ownership Overview
9.33% Insiders
27.79% Mutual Funds
44.52% Other Institutional Investors
18.36% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ZTS FAQ
What was Zoetis’s price range in the past 12 months?
Zoetis lowest stock price was $144.80 and its highest was $200.89 in the past 12 months.
What is Zoetis’s market cap?
Currently, no data Available
When is Zoetis’s upcoming earnings report date?
Zoetis’s upcoming earnings report date is Aug 01, 2024 which is in 75 days.
How were Zoetis’s earnings last quarter?
Zoetis released its earnings results on May 02, 2024. The company reported $1.38 earnings per share for the quarter, beating the consensus estimate of $1.346 by $0.034.
Is Zoetis overvalued?
According to Wall Street analysts Zoetis’s price is currently Undervalued.
Does Zoetis pay dividends?
Zoetis pays a Quarterly dividend of $0.43 which represents an annual dividend yield of 0.93%. See more information on Zoetis dividends here
What is Zoetis’s EPS estimate?
Zoetis’s EPS estimate is $1.5.
How many shares outstanding does Zoetis have?
Zoetis has 456,295,140 shares outstanding.
What happened to Zoetis’s price movement after its last earnings report?
Zoetis reported an EPS of $1.38 in its last earnings report, beating expectations of $1.346. Following the earnings report the stock price went up 5.508%.
Which hedge fund is a major shareholder of Zoetis?
Among the largest hedge funds holding Zoetis’s share is Intermede Investment Partners Ltd. It holds Zoetis’s shares valued at 156M.
---
Zoetis Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$205.00 (17.78% Upside)
$205.00 (17.78% Upside)
Blogger Sentiment
Bullish
ZTS Sentiment 94%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 245.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days <0.1%
Last 30 Days ▲ 1.6%
Last 30 Days ▲ 1.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-1.77%
12-Months-Change
Fundamentals
Return on Equity
50.06%
Trailing 12-Months
Asset Growth
4.32%
Trailing 12-Months
Company Description
Zoetis
Founded in 1952, New Jersey-based Zoetis, Inc. is the world's largest manufacturer of medicine and vaccinations for pets and livestock in the United States and internationally. Its products are complemented by diagnostic products, genetic tests, bio devices and services.
---
ZTS Company Deck
---
ZTS Earnings Call
Q1 2024
0:00 / 0:00
---
ZTS Revenue Breakdown
22.79% Parasiticides
20.73% Vaccines
16.70% Dermatology
14.98% Other pharmaceuticals
24.80% Other
---
ZTS Stock 12 Month Forecast
Average Price Target
$205.00
▲(17.78% Upside)
Technical Analysis
Best Analysts Covering ZTS
1 Year
1 Year Success Rate
9/10 ratings generated profit
1 Year Average Return
+19.98%
reiterated a buy rating 2 days ago
Copying Steve Scala's trades and holding each position for 1 Year would result in 90.00% of your transactions generating a profit, with an average return of +19.98% per trade.
---